{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-053318","form_type":"8-K","ticker":"MRNA","cik":"0001682852","company_name":"Moderna, Inc.","filed_at":"2025-11-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.140424+00:00","generated_at":"2026-05-16T18:04:10.597510+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Moderna targets up to 10% revenue growth in 2026; closes $1.5B loan facility","bullets":["Targets up to 10% revenue growth in 2026; expanding seasonal vaccine franchise to up to six approved products by 2028.","Reducing 2026 and 2027 GAAP operating expenses by ~$0.5B each year on path to cash breakeven in 2028.","Closed a five-year $1.5B term loan facility from Ares Management Credit Funds; initial draw $0.6B.","Discontinues four pipeline programs: CMV, HSV, VZV, and GSD1a; advances nine oncology Phase 2/3 studies.","Updated 2025 year-end cash guidance to $7.1-$7.6B (from $6.5-$7.0B) due to loan draw."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-053318","json":"https://secwatch.observer/filing/0001628280-25-053318.json","markdown":"https://secwatch.observer/filing/0001628280-25-053318.md","text":"https://secwatch.observer/filing/0001628280-25-053318.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1682852/000162828025053318/0001628280-25-053318-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1682852/000162828025053318/mrna-20251120.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T18:04:10.597510+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}